Company Profile
Seres Therapeutics Stock Price, News & Analysis
- Ticker:
- MCRB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.82 USD (-3.70%)
Close
Last updated: August 6, 2026
71M USD
Market cap
Why the stock is moving
Following the latest company update, “Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs”, MCRB closed down 4.67% at $5.00 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Live Biotherapeutic Platform
Seres Therapeutics develops live biotherapeutics that alter the gut microbiome to treat inflammatory and immune-mediated disease. The company previously led development of VOWST, the first orally administered FDA-approved microbiome therapeutic, before divesting it to Nestlé Health Science.
SER-155
SER-155 is a defined bacterial consortium intended to reduce serious infections and modulate immune complications in vulnerable patients. It is Phase 2 ready for prevention of bloodstream infections after allogeneic hematopoietic stem-cell transplantation and has received Breakthrough Therapy and Fast Track designations.
Checkpoint-Inhibitor Enterocolitis
An investigator-sponsored trial at Memorial Sloan Kettering is evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis. This program tests whether the candidate can address a severe inflammatory toxicity associated with cancer immunotherapy and potentially open adjacent immune-disease indications.
SER-603
SER-603 is a preclinical live biotherapeutic program for inflammatory bowel disease. Seres is conducting IND-enabling work and seeking collaborators to support development as a monotherapy or combination treatment.
Future catalysts
Clinical data from the completed investigator-sponsored SER-155 enterocolitis study expected in the coming weeks.
Recent news
- 01
- 02
- 03
- 04
- 05
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Source: Seres Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Seres Therapeutics (MCRB)?
Seres Therapeutics (MCRB) most recently closed at 4.82 USD, a -3.70% move versus the previous session.
What is the market cap of Seres Therapeutics (MCRB)?
Seres Therapeutics currently has a market capitalization of 71M USD on BioPharmSignal.
What does Seres Therapeutics do?
Live Biotherapeutic Platform Seres Therapeutics develops live biotherapeutics that alter the gut microbiome to treat inflammatory and immune-mediated disease. The company previously led development of VOWST, the first orally administered FDA-approved microbiome therapeutic, before divesting it to Nestlé Health Science. SER-155 SER-155 is a defined bacterial...
On which exchange is MCRB stock listed?
Seres Therapeutics (MCRB) is associated with NASDAQ, United States, Biopharma.
What is SER-155?
Clinical data from the completed investigator-sponsored SER-155 enterocolitis study expected in the coming weeks.
Which conditions is Seres Therapeutics targeting with SER-155?
Seres Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Seres Therapeutics describe recent progress with SER-155?
Clinical data from the completed investigator-sponsored SER-155 enterocolitis study expected in the coming weeks.
What is SER-603?
SER-603 SER-603 is a preclinical live biotherapeutic program for inflammatory bowel disease.